Biotechnology
Medical
Female CEOs

GlycoMimetics

$10.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.23 (-2.06%) As of 10:35 AM EDT today
-$0.23 (-2.06%) Today

Why Robinhood?

You can buy or sell GlycoMimetics and other stocks, options, ETFs, and crypto commission-free!

About GLYC

GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. Read More The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Employees
50
Headquarters
Rockville, Maryland
Founded
2003
Market Cap
482.32M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
716.60K
High Today
$11.24
Low Today
$10.88
Open Price
$11.21
Volume
66.99K
52 Week High
$17.78
52 Week Low
$8.29

Collections

Biotechnology
Medical
Female CEOs
Health
Technology
2014 IPO
US

GLYC Earnings

-$0.34
-$0.31
-$0.29
-$0.26
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.